Signant Health Launches Signant Biotech

Signant Health has announced the launch of Signant Biotech—an integrated clinical research approach leveraging software and services tailored to the unique needs of small- to mid-sized biopharmaceutical organizations.

Signant Biotech is anchored by a unified technology platform consisting of fully integrated EDC, eCOA, eConsent, RTSM, and telemedicine solutions. Delivered in conjunction with Signant's scientific and regulatory expertise, the technology platform and accompanying services enable customers to scale from local to multinational studies.

Studies using the unified platform can be implemented in typically four to six weeks. Sponsors and contract research organizations (CROs) can also elect to deliver studies using a self-service model. Either approach is enabled by a configurable designer tool that allows non-technical staff to build studies without software coding. The designer leverages a library of pre-built forms and edit checks which further accelerates study builds.

"We know that small- to mid-sized biopharma sponsors have unique needs," said Graciela Racaro, chief operating officer of Signant in a press. "They want to work with a partner who can balance flexibility and standards to get them to their readouts as quickly and efficiently as possible. They also want to leverage a partner's experience and lessons learned from similar trial designs and global launches."

"We appreciate that our smaller customers in the biotech segment are in a challenging funding environment, where money comes less easily and at more expense," said Roger Smith, chief executive officer of Signant Health in a press release. "We are pleased to support this segment of customers with technology and services that allow them to focus their precious time and resources on advancing their clinical assets, and not having to make trade-offs between scale, capability, accountability, and value."

Reference

Signant Health Launches Signant Biotech to Accelerate and Streamline Clinical Development for Emerging Biopharmaceutical Organizations. (2023, October 3). Cision PR Newswire.